New drug combo aims to wipe out lingering cancer cells after transplant
NCT ID NCT05091372
Summary
This study is testing whether adding a newer drug called belantamab mafodotin to standard lenalidomide maintenance therapy can better eliminate remaining cancer cells in patients with multiple myeloma who have recently received a stem cell transplant. The goal is to help patients achieve and maintain a state where no cancer cells can be detected, potentially leading to longer periods without disease progression. The trial will enroll 94 newly diagnosed patients who are 60-180 days post-transplant and will monitor them closely for safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77051, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.